Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis

Journal of Rheumatology

Volumn 29, Issue 5, 2002, Pages 1071-1078

  Muzaffer, Mohammed A ^a   Dayer, Jean Michel ^a   Feldman, Brian M ^a   Pruzanski, Waldemar ^a   Roux Lombard, Pascale ^a   Schneider, Rayfel ^a   Laxer, Ronald M ^a   Silverman, Earl D ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Cytokines; Inflammation; Interleukin 1 receptor antagonist; Juvenile rheumatoid arthritis; Soluble receptors; Tumor necrosis factor

Indexed keywords

CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; INFLAMMATION; JOINT EFFUSION; JUVENILE RHEUMATOID ARTHRITIS; MALE; PHENOTYPIC VARIATION; POLYARTHRITIS; PRIORITY JOURNAL;

ADULT; ANTIGENS, CD; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; FEMALE; HEMOGLOBINS; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; PREDICTIVE VALUE OF TESTS; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SEVERITY OF ILLNESS INDEX; SIALOGLYCOPROTEINS; SOLUBILITY;

EID: 0036252659     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. What's in a name: Nomenclature of juvenile arthritis. A North American view
2. Juvenile chronic arthritis - A time for change?
3. Clinical and genetic evidence that juvenile arthritis is not a single disease
4. Juvenile rheumatoid arthritis: Ethnic differences in diagnostic types
5. The nomenclature of juvenile arthritis
6. Immune abnormalities in the pathogenesis of juvenile rheumatoid arthritis
7. The cytokine network in juvenile chronic arthritis
8. Serum p55 and p75 tumor necrosis factor receptors as markers of disease activity in juvenile chronic arthritis
9. Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4
10. Local synthesis of both macrophage and T cell cytokines by synovial fluid cells from children with juvenile rheumatoid arthritis
11. Inflammatory cytokine responses in juvenile chronic arthritis
12. Interleukin-1, -6, and -8 levels in juvenile chronic arthritis
13. Interleukin 6 and autoantibodies in juvenile rheumatoid arthritis
14. Study of IL-2, IL-6, TNF alpha, IFN gamma and beta in the serum and synovial fluid of patients with juvenile chronic arthritis
15. Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis
16. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis
17. Serum interleukin-6 levels and joint involvement in polyarticular and pauciarticular juvenile chronic arthritis
18. A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis
19. Cytokine levels in serum and synovial fluid of patients with juvenile rheumatoid arthritis
20. Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy
21. Cytokines in juvenile chronic arthritis
22. Measuring circulating cytokines
23. Interleukin-1 beta (IL-1 beta), IL-1 receptor antagonist, and TNF alpha production in whole blood
24. Interference of soluble TNF-alpha receptors in immunological detection of tumor necrosis factor-alpha
25. Soluble murine IL-1 receptor type I induces release of constitutive IL- 1 alpha
26. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist
27. Elevated levels of soluble interleukin-1 receptor type II and interleukin-1 receptor antagonist in patients with chronic arthritis: Correlations with markers of inflammation and joint destruction
28. Balance of IL-1 receptor antagonist/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL-10
29. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis
30. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis
31. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis
32. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids
33. Dynamics of fever and the cytokine network in systemic juvenile arthritis
34. Soluble interleukin-2 receptor in juvenile rheumatoid arthritis
35. Monoclonal antibody based enzyme-linked and chemiluminescent assays for the human interleukin-1 receptor antagonist. Application to measure hIL-1ra levels in monocyte cultures and synovial fluids
36. Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid
37. Prolactin and interleukin 6 in prepubertal girls with juvenile chronic arthritis
38. Soluble tumor necrosis factor receptor levels reflect coagulation abnormalities in systemic juvenile chronic arthritis
39. Differential effects of IL-6 on systemic and central production of TNF: A study with IL-6-deficient mice
40. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease?
41. Inflammatory cytokines and cytokine antagonists in whole blood cultures of patients with systemic juvenile chronic arthritis
42. Contrasting cytokine profiles in the synovium of different forms of juvenile rheumatoid arthritis and juvenile spondyloarthropathy: Prominence of interleukin 4 in restricted disease
43. Cytokines in juvenile rheumatoid arthritis
44. Study of pro-inflammatory (TNF-alpha, IL-1 alpha, IL-6) and T-cell-derived (IL-2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: Correlations with clinical and laboratory parameters
45. Circulating levels of interleukin 1 beta and of interleukin 1 receptor antagonist in systemic juvenile chronic arthritis
46. Inhibitors of interleukin 1 activity in synovial fluids and in cultured synovial fluid mononuclear cells
47. Joint inflammation and cartilage destruction may occur uncoupled
48. Treatment of rheumatoid arthritis with IL-1 inhibitors
49. Lessons for joint destruction from animal models
50. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: Induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55
51. Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis
52. Increased incidence of neutralizing autoantibodies against interleukin-1 alpha in nondestructive chronic polyarthritis
53. Induction of circulating soluble tumor necrosis factor receptor and interleukin 1 receptor antagonist following interleukin 1 alpha infusion in humans